Skip to main content Skip to navigation
BV421 Rat Anti-Mouse RANKL/TRANCE
Alert icon
If you're planning to order more than 10 BD OptiBuild™ Reagents, please contact your local sales representative to place this order. Contact Us #
BV421 Rat Anti-Mouse RANKL/TRANCE
Flow cytometric analysis using BD OptiBuild™ BV421 Rat Anti-Mouse RANKL/TRANCE (CD254)  antibody (Cat. No. 740089; solid line histogram) on live BALB/c mouse splenocytes stimulated by ConA for 3 days, with autofluorescence control (dotted line histogram). Flow cytometry was performed using a BD LSRFortessa™ Flow Cytometer System.
Flow cytometric analysis using BD OptiBuild™ BV421 Rat Anti-Mouse RANKL/TRANCE (CD254)  antibody (Cat. No. 740089; solid line histogram) on live BALB/c mouse splenocytes stimulated by ConA for 3 days, with autofluorescence control (dotted line histogram). Flow cytometry was performed using a BD LSRFortessa™ Flow Cytometer System.
Product Details
Down Arrow Up Arrow


BD OptiBuild™
TRANCE; TRANCEODF; OPGL; sOdf; CD254; OPTB2; hRANKL2
Mouse (Tested in Development)
Rat IgG2a
Mouse recombinant RANKL
Flow cytometry (Qualified)
0.2 mg/ml
AB_2870634
Aqueous buffered solution containing ≤0.09% sodium azide.
RUO


Preparation And Storage

Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated with BD Horizon BV421 under optimal conditions that minimize unconjugated dye and antibody.

Recommended Assay Procedures

For optimal and reproducible results, BD Horizon Brilliant Stain Buffer should be used anytime two or more BD Horizon Brilliant dyes (including BD OptiBuild Brilliant reagents) are used in the same experiment.  Fluorescent dye interactions may cause staining artifacts which may affect data interpretation.  The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions.  More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794).

Product Notices

  1. This antibody was developed for use in flow cytometry.
  2. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
  3. Researchers should determine the optimal concentration of this reagent for their individual applications.
  4. An isotype control should be used at the same concentration as the antibody of interest.
  5. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
  6. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
  7. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
  8. BD Horizon Brilliant Stain Buffer is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,575,303; 8,354,239.
  9. BD Horizon Brilliant Violet 421 is covered by one or more of the following US patents: 8,158,444; 8,362,193; 8,575,303; 8,354,239.
  10. Pacific Blue™ is a trademark of Molecular Probes, Inc., Eugene, OR.
740089 Rev. 1
Antibody Details
Down Arrow Up Arrow
IK22-5

The IK22-5 monoclonal antibody specifically recognizes CD254, which is also known as, Receptor Activator of NF-kB Ligand (RANKL), TNF-Related Activation-Induced Cytokine Receptor (Trance), Osteoprotegerin Ligand (OPGL), or Osteoclast Differentiation Factor (ODF). CD254/RANKL is likewise known as Tnfsf11, a member of the tumor necrosis factor family. RANKL has been implicated in interactions between T cells and dendritic cells. RANKL binds to RANK expressed on dendritic cells and upregulates the expression of anti-apoptotic protein BcL-XL suggesting a role in dendritic cell survival.  RANKL is also important in T- and B-cell maturation. RANKL can both activate mature osteoclasts and mediate osteoclastogenesis. OPGL-deficient mice show severe osteoporosis and complete absence of osteoclasts as a result of lack of osteogenesis.  It is expressed abundantly by mouse activated T cells, not B cells.  It is also expressed on osteoclasts.

The antibody was conjugated to BD Horizon™ BV421 which is part of the BD Horizon Brilliant™ Violet family of dyes. With an Ex Max of 407-nm and Em Max at 421-nm, BD Horizon BV421 can be excited by the violet laser and detected in the standard Pacific Blue™ filter set (eg, 450/50-nm filter). BD Horizon BV421 conjugates are very bright, often exhibiting a 10 fold improvement in brightness compared to Pacific Blue conjugates.

740089 Rev. 1
Format Details
Down Arrow Up Arrow
BV421
The BD Horizon Brilliant Violet™ 421 (BV421) Dye is part of the BD Horizon Brilliant Violet™ family of dyes. This polymer-technology based dye has an excitation maximum (Ex Max) of 407-nm and an emission maximum (Em Max) at 423-nm. Driven by BD innovation, BV421 is designed to be excited by the violet laser (405-nm) and detected using an optical filter centered near 420-nm (e.g., a 431/28-nm or 450/50-nm bandpass filter). BV421 is an ideal alternative for V450 as it is approximately ten times brighter with less spillover into the BV510/V500 detector. Please ensure that your instrument’s configurations (lasers and optical filters) are appropriate for this dye.
altImg
BV421
Violet 405 nm
407 nm
423 nm
740089 Rev.1
Citations & References
Down Arrow Up Arrow

Development References (3)

  1. Ando T, Ichikawa J, Wako M et al. TWEAK/Fn14 interaction regulates RANTES production, BMP-2-induced differentiation, and RANKL expression in mouse osteoblastic MC3T3-E1 cells. Arthritis Res Ther. 2006; 8(5):R146. (Biology). View Reference
  2. Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. 2004; 292(4):490-495. (Biology). View Reference
  3. Kamijo S, Nakajima A, Ikeda K et al. Amelioration of bone loss in collagen-induced arthritis by neutralizing anti-RANKL monoclonal antibody. Biochem Biophys Res Commun. 2006; 347(1):124-132. (Clone-specific). View Reference
740089 Rev. 1

Please refer to Support Documents for Quality Certificates


Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described


Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

For Research Use Only. Not for use in diagnostic or therapeutic procedures.